{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["penpulimab","anlotinib"]],"indication":"first-line metastatic pancreatic adenocarcinoma","name":"RCT-PAAG","nct_id":"NCT06051851","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rct-paag-nct06051851. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RCT-PAAG","arms":[{"description":"penpulimab in combination with anlotinib and AG regimen in the first-line treatment of advanced metastatic pancreatic cancer","label":"Trial group","type":"EXPERIMENTAL"},{"description":"AG regimen in the first-line treatment of advanced metastatic pancreatic cancer","label":"Control group","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-07-01","type":"ESTIMATED"},"conditions":["Pancreatic Adenocarcinoma Metastatic"],"enrollment":{"count":177,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Penpulimab","otherNames":[],"type":"DRUG"},{"name":"Anlotinib","otherNames":[],"type":"DRUG"},{"name":"Nab paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"}],"last_update":"2023-09-25","lead_sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","official_title":"Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine (PAAG) as First-line Treatment for Advanced Metastatic Pancreatic Cancer: a Prospective, Multicenter, Single-arm, Phase 2 Study","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2025-07-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival（PFS）","timeFrame":"up to 1 years"}],"references":[],"start_date":{"date":"2023-07-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer","url":"https://clinicaltrials.gov/study/NCT06051851"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rct-paag-nct06051851"}